论文部分内容阅读
对穿透性角膜移植术后患者合理应用环胞霉素Ａ滴眼液代替地塞米松滴眼液的疗效和眼压进行评价。方法：４２０例穿透性角膜移植术后患者，随机分成两组。Ａ组：０．５％地塞米松滴眼液联合１％环胞霉素Ａ滴眼液，每天４次，共３个月。Ｂ组：０．５％地塞米松滴眼液联合１％环胞霉素Ａ滴眼液，每天４次，共１个月，后改用１％环胞霉素Ａ滴眼液至３个月。对两组眼压和免疫排斥情况进行观察。结果：Ａ组５８例患者眼压＞２２ｍｍＨｇ，占２５％；Ｂ组９例眼压＞２２ｍｍＨｇ，占５％。两组眼压统计（Ｐ＜０．００１），有非常显著性差异。停用０．５％地塞米松滴眼液后，１～２周大部分患者眼压降至正常。两组免疫排斥反应率无差异。结论：局部应用１％环胞霉素Ａ滴眼液代替皮质类固醇滴眼液能有效控制角膜移植术后排斥反应和避免皮质类固醇性青光眼的发生
To evaluate the curative effect and intraocular pressure (IOP) of cyclosporine A eye drops instead of dexamethasone eye drops in patients after penetrating keratoplasty. Methods: 420 patients with penetrating keratoplasty were randomly divided into two groups. Group A: 0.5% dexamethasone eye drops combined with 1% cyclosporin A eye drops 4 times a day for 3 months. Group B: 0.5% dexamethasone eye drops combined with 1% cyclosporin A eye drops 4 times a day for a total of 1 month, then changed to 1% cyclosporin A eye drops to 3 month. The two groups of intraocular pressure and immune rejection were observed. Results: The intraocular pressure of 58 patients in group A was> 22 mmHg, accounting for 25%. The intraocular pressure in group B was> 22 mmHg, accounting for 5%. Intraocular pressure statistics (P <0.001), there is a very significant difference. After stopping 0.5% dexamethasone eye drops, the intraocular pressure of most patients in 1-2 weeks decreased to normal. There was no difference in the rate of immune rejection between the two groups. CONCLUSION: Topical application of 1% cyclosporine A eye drops instead of corticosteroid eye drops can effectively control the rejection after corneal transplantation and avoid the occurrence of corticosteroid glaucoma